A pair of Rutgers professors have partnered with a former colleague to form a startup with the goal of developing novel cancer treatments based on the use of antibody drug conjugates.
Rutgers Office for Research’s Innovation Ventures has executed an exclusive license agreement between the university and Sauvie BiKE, LLC, a subsidiary of Sauvie Inc., to develop and commercialize a bi-specific natural killer cell engager technology in the field of oncology.
A drone that can fly, float, swim, dive, and transition between air and water in less than a second. Technology that can change the genetic code at the individual base level in a cell or an organism. These two innovations, both invented at Rutgers, The State University of New Jersey, received 2022 Edison Patent Awards at the Research & Development Council of New Jersey annual banquet on Thursday, Nov. 3.
Rutgers Innovation Ventures has executed an exclusive license between Rutgers, The State University of New Jersey and the startup RenewCO2.
A pair of Rutgers startups have received a grant from the New Jersey Commission on Science, Innovation, and Technology (CSIT) as part of the organization’s Catalyst Seed Research and Development (R&D) Grant and Clean Tech Seed Grant programs. The program awarded a combined total of just under $4 million in grants to 45 startups in New Jersey, with the goal of supporting the companies’ efforts to advance their technologies closer to the marketplace.
As a public research university, Rutgers also serves as a research hub for the Garden State and beyond, providing integrated support and resources for innovators and established or emerging companies seeking to advance critical R&D goals. Among these resources is Rutgers Core Services, offering specialized laboratories with state-of-the-art equipment, unique instrumentation and shared services managed by scientists with technical expertise and experience and available on a fee-for-service basis.
A Rutgers professor’s novel research into targeting and silencing defective, disease-causing RNA molecules has led to the launch of Ceptur Therapeutics, a startup that has raised $75 million in Series A funding.